Recent Updates
Recently added Catalysts
MYO Positive Sentiment

Myomo to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Tuesday, September 1, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Myomo, Inc. has announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14-16, 2026, at the Lotte Palace Hotel in New York. The company aims to highlight its advancements in wearable medical robotics designed for individuals with neurological disorders and upper-limb paralysis. This event is expected to enhance Myomo's visibility in the investment community.

Market Sentiment Analysis

POSITIVE FACTORS

  • Myomo is participating in a prestigious investment conference.
  • The event provides a platform for Myomo to showcase its innovations.
  • Increased visibility may attract potential investors.

Full Press Release Details

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced its participation at the H.C. Wainwright 28th Annual Global Investment Conference being held September 14-16, 2026 at the Lotte Palace Hotel in New York. Myomo’s President and Chief Executive Officer Paul Gudonis and Chief Financial Officer

Frequently Asked Questions

When is Myomo presenting at the conference?

Myomo will present at the H.C. Wainwright conference from September 14-16, 2026.

Where is the H.C. Wainwright conference held?

The conference will take place at the Lotte Palace Hotel in New York.

Who will represent Myomo at the event?

Myomo's President and CEO Paul Gudonis will represent the company.

What does Myomo specialize in?

Myomo specializes in wearable medical robotics for neurological disorders.

ShareAdd on Google
Tags: MYO Viatris Investor Conferences Healthcare Myomo H.C. Wainwright investment conference wearable robotics neurological disorders
Last updated: Sep 1, 2026

Biotech snapshot

Cash runway
$13M liquidity · $1M/mo burn
~20 mo
Low dilution risk